摘要
免疫检查点抑制剂(ICIs)为新型免疫治疗药物,能够有效阻断免疫抑制,极大改善晚期恶性肿瘤患者的生存及预后。随着ICIs广泛应用,由其引发的免疫相关不良反应(irAEs)不断增多。irAEs的发生时间从数天到数月不等,且可能累及机体不同的器官或系统,不仅可影响肿瘤治疗进程,少数严重irAEs还具有致死性。目前,irAEs的具体发生机制尚未阐明,且其临床表现多样,总体诊断难度较大。本文详细介绍了ICIs相关irAEs的临床特征、预测标志物及治疗原则,并探讨了irAEs与ICIs治疗疗效的相关性。
Immune checkpoint inhibitors(ICIs)are novel immunotherapy regimens that can effectively block immunosuppression.ICIs have greatly improved the survival and prognosis of patients with advanced malignant tumors.However,their wide use has resulted in increased reports of the immune-related adverse events(irAEs).The onset time of irAEs can vary from days to months.IrAEs may involve different organs or systems.IrAEs can interfere with the process of cancer management,including a few serious irAEs that are fatal.For now,specific mechanisms of irAEs have not been elucidated.The clinical manifestations of irAEs are diverse,making the diagnosis difficult.This review summarized the clinical characteristics,spectrum,pathogenesis,predictive biomarkers,management principles,and the correlation between irAEs and the therapeutic effect of ICIS was discussed.
作者
赵喆
唐彦
朱惠娟
陈晓光
ZHAO Zhe;TANG Yan;ZHU Hui-juan;CHEN Xiao-guang*(Department of Pharmacy,Key Laboratory of Endocrinology of National Health Commission,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China;State Key Laboratory of Bioactive Substrate and Function of Natural Medicine,Institute of Materia Medica,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100050,China;Department of Endocrinology,Key Laboratory of Endocrinology of National Health Commission,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China)
出处
《临床药物治疗杂志》
2022年第6期1-6,共6页
Clinical Medication Journal
关键词
免疫检查点抑制剂
免疫相关不良反应
预测标志物
治疗原则
immune checkpoint inhibitor
immune-related adverse event
predictive biomarker
management principle
